Telomeres are TTAGGG-tandem-repeat caps at chromosome ends, protected by the shelterin protein complex (TRF1, TRF2, POT1, TIN2, TPP1, RAP1). Without protection, chromosome ends would be recognized as double-strand DNA breaks and trigger DDR (ATM/ATR + p53/p21) → senescence or apoptosis. The "end-replication problem": DNA polymerase cannot fully replicate the 3' end of the lagging strand → progressive telomere shortening (~50-100 bp per cell division). Without compensation: replicative senescence (Hayflick limit, ~50-60 divisions) → tissue aging phenotypes. Compensation by telomerase: the ribonucleoprotein reverse transcriptase TERT (catalytic) + TERC/TR (RNA template) extends telomeres. Expression: active in germline + stem cells + most cancers (~85-90% of tumors reactivate telomerase); suppressed in most somatic adult cells (limits tumor formation but causes aging). ALT (alternative lengthening of telomeres) pathway: ~10-15% of cancers — homologous recombination-based; common in mesenchymal tumors + osteosarcoma. Disease relevance: dyskeratosis congenita + telomere biology disorders (TERT, TERC, DKC1, TINF2, RTEL1, CTC1 mutations) → bone marrow failure, pulmonary fibrosis, hepatic fibrosis, premature aging. Therapeutic landscape: telomerase inhibition (imetelstat — first-in-class, FDA-approved 2024 for transfusion-dependent MDS); telomerase activators (TA-65 — astragalus-derived, modest evidence); G-quadruplex stabilizers (BRACO-19) preclinical. Lifestyle: chronic stress + smoking + obesity → faster telomere shortening; exercise + Mediterranean diet → slower attrition. Cross-links: senescence sasp senolytics (replicative senescence end-state), apoptosis bcl2 axis (cellular response to uncapped telomeres), hpa axis (chronic stress affects telomere attrition).
Organ Systems
immune-hematologic
reproductive
integumentary
Pathway Steps
TTAGGG telomeric tandem repeats → shelterin complex binding (TRF1/2, POT1, TIN2, TPP1, RAP1) — via caps the chromosome end + prevents DDR misinterpretation as DSB. Chromosome ends are capped by tandem TTAGGG repeats bound by the six-protein shelterin complex (TRF1, TRF2, POT1, TIN2, TPP1, RAP1). Shelterin folds the end into a protective t-loop and hides it from repair machinery — solving the “end-protection problem” so telomeres aren’t mistaken for double-strand breaks.
lagging-strand DNA polymerase → incomplete 3′ end replication → 50–100 bp loss per division — via the "end-replication problem"; primary mechanism of replicative shortening. The end-replication problem: lagging-strand synthesis cannot copy the very 3′ end, so telomeres lose ~50-100 bp each division. This progressive shortening is the molecular clock that limits how many times a somatic cell can divide, counting down toward senescence.
TERT (catalytic) + TERC (RNA template) → telomerase ribonucleoprotein assembly — via reverse transcribes TTAGGG onto the 3′ overhang; active in germline + stem + cancer cells. Telomerase counters shortening: it is a ribonucleoprotein combining the catalytic reverse transcriptase TERT with the RNA template TERC, used to add new TTAGGG repeats. Mutations in TERT/TERC cause telomere-biology disorders (dyskeratosis congenita, pulmonary fibrosis) from premature telomere failure.
telomerase active → telomere extension → cellular replicative lifespan extended — via maintains capacity for division; cancer cells exploit this. When active, telomerase extends telomeres and lifts the replicative limit — which is why it is expressed in germline and stem cells but silenced in most somatic cells. Telomerase reactivation is a near-universal hallmark of cancer, granting malignant cells unlimited proliferation.
telomere shortening past critical threshold → DDR activation (ATM/ATR + p53/p21) — via uncapped telomeres look like DNA double-strand breaks → senescence or apoptosis. Once a telomere shortens past a critical length, shelterin can no longer cap it; the exposed end is read as DNA damage, activating ATM/ATR and the p53/p21 response. So telomere attrition is transduced into a growth-arrest signal through the standard DNA-damage machinery.
replicative senescence (Hayflick limit) → permanent cell-cycle arrest + SASP — via cross-link to senescence sasp senolytics — primary driver of aging phenotype. The result is replicative senescence — the Hayflick limit — a permanent cell-cycle arrest with the senescence-associated secretory phenotype (SASP). This caps proliferative lifespan as a tumor-suppressive barrier, but the accumulation of senescent cells also contributes to organismal aging.